hrp0095p1-313 | Growth and Syndromes | ESPE2022

Pathway to assess severe primary IGF-1 deficiency diagnosis in a real-life setting: data from the Global Increlex® Registry

Bang Peter , Polak Michel , Bossowski Artur , De Schepper Jean , Sert Caroline , Perrot Valérie , Woelfle Joachim

Background: Severe primary insulin-like growth factor-1 deficiency (SPIGFD) is a rare condition for which replacement therapy with recombinant human insulin-like growth factor-1 (rhIGF 1; mecasermin [Increlex®]) is approved for treatment in Europe and the USA. SPIGFD is defined as a height standard deviation score (HtSDS) ≤-3, and baseline IGF-1 <2.5th percentile (European indication) or ≤-3 SDS (USA indication) for age and gender, desp...

hrp0095p2-28 | Bone, Growth Plate and Mineral Metabolism | ESPE2022

Longitudinal assessment of bone health index (BHI) as a measure of bone health in short-statured children before and during treatment with recombinant growth hormone

Holzapfel Lukas , Bettendorf Markus , Rabe Michael , Mittnacht Janna , Choukair Daniela , Schenk Jens-Peter

Introduction: Bone Health Index (BHI) determined by measurement of cortical thickness of metacarpalia II-IV in x-rays of the left hand represents a method to estimate bone health in children. Aim of this study was to investigate changes of BHI SDS in the course of growth hormone (GH) treatment.Method: 256 consecutive children with short stature (isolated GH deficiency (IGHD) n = 121, multiple pituitary hormone deficiency...

hrp0095p2-129 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2022

Molecular pathways linking fetal growth restriction to cardiometabolic risk in childhood

Perchard Reena , Higgins Lucy , Garner Terence , Stevens Adam , Johnstone Edward , Clayton Peter

Background: Cardiometabolic (CM) risk is linked to being small for gestational age (SGA, birthweight <-2SDS). Fetal growth restriction (FGR) may not result in SGA. We focused on potential CM risk in children born following pregnancies at higher risk for FGR.Aims: To identify associations between fetal and childhood weight trajectory quartiles and CM risk markers. 2.To define molecular pathways potentially associated w...

hrp0092fc9.6 | Fetal, Neonatal Endocrinology and Metabolism (to include Hypoglycaemia) | ESPE2019

[18F]F-DOPA-PET/MRI or /CT in Children with Congenital Hyperinsulinism

Empting Susann , Mohnike Konrad , Barthlen Winfried , Michel Peter , Wieland Ilse , Zenker Martin , Mohnike Wolfgang , Mohnike Klaus

Congenital hyperinsulinism (CHI) is a complex heterogeneous disease affecting 1 in 40.000 newborns. Recurrent hypoketotic hypoglycaemia led to permanent mental and motor disabilities in 30-40% of children. Histologically three types had been differentiated: focal, diffuse and atypical. Up to now, only focal-type CHI can be permanently cured by focus removal. Focal-type CHI is characterized by paternal inherited mutation of ABCC8 or KCNJ11 mutations. Therefore mutation anal...

hrp0092fc12.4 | Growth and Syndromes (to include Turner Syndrome) | ESPE2019

Integration of Transcriptomic and Epigenomic Data in Childhood Identifies a Subset of Individuals Born Small for Gestational Age (SGA) with "catch-up" Growth Who Become Pre-Hypertensive in Early Adulthood

Garner Terence , Murray Philip , Sellers Robert , Whatmore Andrew , Clayton Peter , Stevens Adam

Background: Children born SGA are known to develop cardiometabolic conditions in adulthood1. Nothing is known about the relationship of the transcriptome (gene expression) and epigenome (DNA methylation) to birth size and the future development of cardiometabolic disease.Aim: To identify, I) differences and functional links between epigenome age-7years, transcriptome age-9years associated and ...

hrp0092fc12.6 | Growth and Syndromes (to include Turner Syndrome) | ESPE2019

An Integrated Systems Biology Analysis of the Genome, Epigenome and Transcriptome Identifies a Distinct Pattern of Hypermethylation Associated with Low Childhood Growth

Garner Terence , Sellers Robert , Guo Hui , Whatmore Andrew , Clayton Peter , Stevens Adam , Murray Philip

Background: Current data from genome wide association studies (GWAS) explains 24.6% of the variation in adult height from 3290 single nucleotide polymorphisms (SNPs)1. Data on the genetic control of growth velocity during childhood is more limited and no previous studies have linked childhood growth to changes in the transcriptome (gene expression) or epigenome (DNA methylation). Here we present a systems biology approach to understand mid-child...

hrp0092p1-212 | GH and IGFs (1) | ESPE2019

Hypoglycaemia Adverse Events in SPIGFD: Association with Patient Diagnosis, Age, Time-Course and Dosage of Mecasermin: 10-year Data from the European Increlex® Growth Forum Database in Europe (EU-IGFD)

Woelfle Joachim , Polak Michel , Bang Peter , Perrot Valérie , Sert Caroline

Background: In Europe, Increlex® (mecasermin) is approved for treatment of growth failure in children with severe primary insulin-like growth factor-1 deficiency (SPIGFD). We present 10-year data (up to October 2018) from the European Increlex® Growth Forum Database (EU-IGFD) registry (NCT00903110) on the frequency, predictive factors, and the potential impact of hypoglycaemia on efficacy outcomes....

hrp0092p1-214 | GH and IGFs (1) | ESPE2019

The European Increlex® Growth Forum Database (EU-IGFD) Registry: Do Treatment Practices Differ Between European Countries?

Bang Peter , Polak Michel , Woelfle Joachim , Perrot Valérie , Sert Caroline

Background: In the European Union, Increlex® (mecasermin) is approved for the treatment of growth failure in children with severe primary insulin-like growth factor-1 deficiency (SPIGFD).Methods: The European Increlex® Growth Forum Database (EU-IGFD) registry (NCT00903110) is an ongoing, multicentre, open-label, observational study monitoring the safety and efficacy of mecasermin in childr...

hrp0092p1-223 | Growth and Syndromes (to include Turner Syndrome) (1) | ESPE2019

Tall Stature and Macrodactyly of the Great Toes Due to a Novel Mutation in the Natriuretic Peptide Receptor-2 Gene

Lauffer Peter , van Duyvenvoorde Hemine , van Haeringen Arie , van der Kaay Danielle

Background: Mutations in the gene encoding the natriuretic peptide receptor-2 gene (NPR2) are responsible for monogenic growth disorders. Loss-of-function variants cause extreme short stature and skeletal dysplasia. Gain-of-function mutations cause tall stature with - in some cases - macrodactyly of the great toes, a Marfanoid habitus, arachnodactyly and scoliosis. We describe a novel gain-of-function mutation in exon 8 of NPR2 in a family wi...

hrp0092p2-187 | Growth and Syndromes (to include Turner Syndrome) | ESPE2019

"Transition Readiness in Girls and Young Women with Turner Syndrome – are they Less Ready?" Associations between Transition Readiness and Diagnosis

Culen Caroline , Herle Marion , Froehlich-Reiterer Elke , Bluemel Peter , Wagner Gudrun , Ertl Diana-Alexandra , Haeusler Gabriele

Objective: Young women with Turner syndrome are known to be especially at risk for lost of follow-up. Recent literature indicates that there are disparities regarding transition readiness between different chronic conditions. To assess differences in transition readiness might be crucial for identifying special needs in specific patient cohorts when preparing for transfer to adult care. Our hypothesis was, that young women with Turner syndrome would score lowe...